-
公开(公告)号：US06284221B1
公开(公告)日：2001-09-04
申请号：US08733202
申请日：1996-10-18
申请人： Dale B. Schenk , Michael G. Schlossmacher , Dennis J. Selkoe , Peter A. Seubert , Carmen Vigo-Pelfrey
发明人： Dale B. Schenk , Michael G. Schlossmacher , Dennis J. Selkoe , Peter A. Seubert , Carmen Vigo-Pelfrey
IPC分类号： A61K4900
CPC分类号： G01N33/6896 , G01N2800/2821 , Y10S436/811
摘要： A method for identifying inhibitors of the production of &bgr;-amyloid peptides by administration of a compound to a mammalian host is provided.
摘要翻译： 提供了通过向哺乳动物宿主施用化合物来鉴定β-淀粉样蛋白肽生产抑制剂的方法。
-
2.发明授权
公开(公告)号：US5837672A
公开(公告)日：1998-11-17
申请号：US456347
申请日：1995-06-01
申请人： Dale B. Schenk , Michael G. Schlossmacher , Dennis J. Selkoe , Peter A. Seubert , Carmen Vigo-Pelfrey
发明人： Dale B. Schenk , Michael G. Schlossmacher , Dennis J. Selkoe , Peter A. Seubert , Carmen Vigo-Pelfrey
CPC分类号： G01N33/6896 , G01N2800/2821 , Y10S436/811
摘要： Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.
摘要翻译： 可溶性β-淀粉样蛋白肽（beta AP）在生物液体中以非常低的浓度测量，通常在0.1ng / ml至10ng / ml的范围内。 动物或培养细胞的条件培养基中的βAP浓度的测量可用于药物筛选，其中将测试化合物施用于动物或暴露于培养的细胞，并观察动物或培养基中βAP的积累。 已经发现体液中的βAP水平升高如血液和脑脊液与患者中诸如阿尔茨海默氏病之类的βAP相关病症的存在相关。 用于诊断和监测β-AP相关病症的方法包括测量来自患者的这种体液中的βAP的水平。
-
3.发明授权Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau 失效通过测量淀粉样蛋白-β肽（x→41）和tau来帮助诊断阿尔茨海默病的方法公开(公告)号：US07427392B1
公开(公告)日：2008-09-23
申请号：US08466554
申请日：1995-06-06
IPC分类号： A61K49/00
CPC分类号： C07K16/18 , C07K14/4711 , G01N33/6896 , G01N2333/4709 , G01N2500/00 , G01N2800/2821 , Y10S436/811
摘要： This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-β peptide (x−≧41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both Aβ(x−≧41) and tau. Low levels of Aβ(x−≧41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of Aβ(x−≧41) and low levels of tau are a negative indication of Alzheimer's disease.
摘要翻译： 本发明提供了有助于诊断阿尔茨海默病的方法。 该方法涉及测量患者脑脊液中淀粉样蛋白-β肽的量（x→41）。 高水平的肽通常与阿尔茨海默病的诊断不一致。 低水平的肽与疾病一致，并且与其他检测可以提供阳性诊断。 其他方法涉及测量Abeta（x→41）和tau的量。 低水平的Abeta（x - > = 41）和高水平的tau是阿尔茨海默病的阳性指标，而高水平的Abeta（x> = 41）和低水平的tau是阿尔茨海默病的阴性指标。
-
4.发明授权Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau 有权通过测量淀粉样蛋白来帮助诊断阿尔茨海默病的方法 肽（x-≥41）和tau公开(公告)号：US07811769B2
公开(公告)日：2010-10-12
申请号：US10879958
申请日：2004-06-28
IPC分类号： G01N33/53
CPC分类号： C07K16/18 , C07K14/4711 , G01N33/6896 , G01N2333/4709 , G01N2500/00 , G01N2800/2821 , Y10S436/811
摘要： This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-β peptide (x−≧41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both Aβ(x−≧41) and tau. Low levels of Aβ(x−≧41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of Aβ(x−≧41) and low levels of tau are a negative indication of Alzheimer's disease.
摘要翻译： 本发明提供了有助于诊断阿尔茨海默病的方法。 该方法涉及测量淀粉样蛋白的量 肽（x-≧41）在患者的脑脊液中。 高水平的肽通常与阿尔茨海默病的诊断不一致。 低水平的肽与疾病一致，并且与其他检测可以提供阳性诊断。 其他方法包括测量A＆Bgr（x-≥41）和tau的量。 低水平的A＆bgr（x-≧41）和高水平的tau是阿尔茨海默病的阳性指标，而高水平的A＆bgr（x-≧41）和低水平的tau是阿尔茨海默氏病的阴性指标。
-
5.发明授权Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreq.41) 失效通过测量淀粉样蛋白β肽来帮助诊断阿尔茨海默病的方法（x→41）
公开(公告)号：US06114133A
公开(公告)日：2000-09-05
申请号：US339141
申请日：1994-11-14
CPC分类号： C07K16/18 , C07K14/4711 , G01N33/6896 , G01N2800/2821 , Y10S436/811
摘要： This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-.beta. peptide (x-.gtoreq.41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis.
摘要翻译： 本发明提供了有助于诊断阿尔茨海默病的方法。 该方法包括测量患者脑脊液中淀粉样蛋白-β肽（x - > / = 41）的量。 高水平的肽通常与阿尔茨海默病的诊断不一致。 低水平的肽与疾病一致，并且与其他检测可以提供阳性诊断。
-
公开(公告)号：US5593846A
公开(公告)日：1997-01-14
申请号：US437067
申请日：1995-05-09
IPC分类号： A61K38/00 , C07K14/47 , C07K16/18 , G01N33/50 , G01N33/68 , G01N33/53 , G01N33/537 , G01N33/543
CPC分类号： C07K14/4711 , C07K16/18 , G01N33/5008 , G01N33/6896 , A61K38/00 , G01N2333/4709 , G01N2500/10 , G01N2800/2821 , Y10S436/811
摘要： Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.
摘要翻译： 可溶性β-淀粉样蛋白肽（beta AP）在生物液体中以非常低的浓度测量，通常在0.1ng / ml至10ng / ml的范围内。 动物或培养细胞的条件培养基中的βAP浓度的测量可用于药物筛选，其中将测试化合物施用于动物或暴露于培养的细胞，并观察动物或培养基中βAP的积累。 已经发现体液中的βAP水平升高如血液和脑脊液与患者中诸如阿尔茨海默氏病之类的βAP相关病症的存在相关。 用于诊断和监测β-AP相关病症的方法包括测量来自患者的这种体液中的βAP的水平。
-
7.发明授权Methods for determining whether a compound alters the amount of at least one αβ (X-41) peptide and the amount of either total αβ or at least one αβ (X-40) peptide produced by a non-human mammal 失效用于确定化合物是否改变至少一种α和bgr的量的方法; （X-41）肽和总α和bgr的量; 或至少一个α＆bgr; （X-40）肽公开(公告)号：US07993627B2
公开(公告)日：2011-08-09
申请号：US10335035
申请日：2002-12-30
IPC分类号： A61K49/00
CPC分类号： C07K14/4711 , A61K38/00 , C07K16/18 , G01N33/6896 , G01N2333/4709 , G01N2500/00 , G01N2500/10 , G01N2800/2821
摘要： This invention provides methods of screening compounds for their ability to alter the production of Aβ(x≧41) alone or in combination with Aβ(x≦40). The methods involve administering compounds to cells, specifically measuring the amounts of Aβ(x≦40) and Aβ(x≧41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.
摘要翻译： 本发明提供了筛选化合物单独或与A＆bgr（x＆amp; 40; 40）组合改变A＆Bgr（x≥41）的生产能力的方法。 所述方法包括给细胞施用化合物，特异性地测量由细胞产生的A＆bgr（x＆lt; 40; 40）和A＆bgr（x≥41）的量，并且将这些量与由细胞产生的量进行比较，而不施用化合物。
-
8.发明授权Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (X->41) and tau 失效通过测量淀粉样蛋白来帮助诊断阿尔茨海默病的方法 肽（X-> 41）和tau公开(公告)号：US07700309B2
公开(公告)日：2010-04-20
申请号：US10964484
申请日：2004-10-12
IPC分类号： G01N33/53
CPC分类号： C07K16/18 , C07K14/4711 , G01N33/6896 , G01N2333/4709 , G01N2500/00 , G01N2800/2821 , Y10S436/811
摘要： This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-β peptide (x-≧41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both Aβ(x-≧41) and tau. Low levels of Aβ(x-≧41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of Aβ(x-≧41) and low levels of tau are a negative indication of Alzheimer's disease.
摘要翻译： 本发明提供了有助于诊断阿尔茨海默病的方法。 该方法涉及测量淀粉样蛋白的量 肽（x-≧41）在患者的脑脊液中。 高水平的肽通常与阿尔茨海默病的诊断不一致。 低水平的肽与疾病一致，并且与其他检测可以提供阳性诊断。 其他方法包括测量A和Bgr（x-≥41）和tau的量。 低水平的A＆bgr（x-≧41）和高水平的tau是阿尔茨海默病的阳性指标，而高水平的A＆bgr（x-≧41）和低水平的tau是阿尔茨海默氏病的阴性指标。
-
9.发明授权Screening compounds for the ability to alter the production of amyloid-&bgr; peptide 失效筛选化合物以改变淀粉样蛋白-β肽的产生能力公开(公告)号：US06610493B1
公开(公告)日：2003-08-26
申请号：US08665649
申请日：1996-06-18
申请人： Martin Citron , Dennis J. Selkoe , Peter A. Seubert , Dale Schenk
发明人： Martin Citron , Dennis J. Selkoe , Peter A. Seubert , Dale Schenk
IPC分类号： G01N3353
CPC分类号： C07K14/4711 , A61K38/00 , C07K16/18 , G01N33/6896 , G01N2333/4709 , G01N2500/00 , G01N2500/10 , G01N2800/2821
摘要： This invention provides methods of screening compounds for their ability to alter the production of A&bgr;(x≧41) alone or in combination with A&bgr;(x≦40). The methods involve administering compounds to cells, specifically measuring the amounts of A&bgr;(x≦40) and A&bgr;(x≧41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.
摘要翻译： 本发明提供了筛选化合物单独或与Abeta（x <= 40）组合改变Abeta（x> = 41）产生能力的方法。 所述方法包括给细胞施用化合物，特异性地测量由细胞产生的Abeta（x <= 40）和Abeta（x> = 41）的量，并将这些量与由细胞产生的量进行比较，而不施用化合物。
-
公开(公告)号：US20110218328A1
公开(公告)日：2011-09-08
申请号：US13032412
申请日：2011-02-22
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K39/0008 , A61K49/00 , A61K49/16 , A61K51/1018 , A61K2039/505 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92 , Y10S530/809
摘要： Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.037 秒)
